Brain scans track Parkinson progression
- Trial ID
- NCT05516719
- Official Title
- Longitudinal Investigation of Imidazoline-2 Binding Site as a Novel Marker of Disease Progression in Parkinson's Disease: An [11C]BU99008 PET Study
- Goal
- Brain scans track Parkinson progression
- Status
- RECRUITING
- Sponsor
- University of Exeter
- Study Type
- OBSERVATIONAL
- Enrollment
- 44 participants
- Conditions
- Parkinson's, Parkinson Disease, Parkinson's Disease, Neurodegenerative Diseases, Neurodegeneration, Positron Emission Tomography
- Interventions
- Positron Emission Tomography (PET) scan using BU99008 tracer, FP-CIT Single-photon Emission Computed Tomography (SPECT) scan, Magnetic Resonance Imaging (MRI) Scan, Lumbar puncture
Plain-Language Summary
They're testing whether imaging a brain protein called the imidazoline-2 binding site can track Parkinson's progression over time, so we might have a reliable biomarker of disease stage and change. Participants get PET scans with the [11C]BU99008 tracer that binds to I2BS so the images show where and how much of that target is present in the brain. They also have dopamine transporter SPECT, MRI, and lumbar puncture so researchers can compare I2BS signal with dopamine loss and CSF biomarkers, and the tracer is for imaging only so it does not treat Parkinson's or interact with levodopa, though some drugs that affect I2BS or DaT imaging must be paused before scans. The study is looking for adults 25 and older with Parkinson's who can consent and tolerate scans and lumbar puncture, and it excludes people with dementia, certain medications or bleeding risks, or other conditions that make MRI or lumbar puncture unsafe.
Locations
- University Of Exeter, Exeter, Devon, United Kingdom
Frequently Asked Questions
- What is this trial testing?
- This trial is studying Positron Emission Tomography (PET) scan using BU99008 tracer. They're testing whether imaging a brain protein called the imidazoline-2 binding site can track Parkinson's progression over time, so we might have a reliable biomarker of disease stage and change. Participants get PET scans with the [11C]BU99008 tracer that binds to I2BS so the images show where and how much of that target is present in the brain. They also have dopamine transporter SPECT, MRI, and lumbar puncture so researchers can compare I2BS signal with dopamine loss and CSF biomarkers, and the tracer is for imaging only so it does not treat Parkinson's or interact with levodopa, though some drugs that affect I2BS or DaT imaging must be paused before scans. The study is looking for adults 25 and older with Parkinson's who can consent and tolerate scans and lumbar puncture, and it excludes people with dementia, certain medications or bleeding risks, or other conditions that make MRI or lumbar puncture unsafe.
- Who can participate?
- Participants must be at least 25 Years.
- Where is this trial located?
- This trial is recruiting at 1 location.
- Does it cost anything to join?
- No. There is no cost to participate. Study-related care and treatment are provided at no charge.
- How long does the trial last?
- This trial is estimated to last approximately 4 years and 8 months.